Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ Contracts
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH NIDA
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N98026R00138
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AJ11
Additional Details
Documents1
The National Institute on Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services, has issued a presolicitation notice regarding the Pharmacology and Toxicology for Therapeutics Program (PTTP) Indefinite Delivery/Indefinite Quantity (IDIQ) contracts. This notice, identified by procurement number 75N98026R00138, announces the government’s intent to modify and extend the ordering period for four existing IDIQ contracts by two years, from September 12, 2026, to September 12, 2028. The affected contracts are currently held by SRI International, Southern Research, IIT Research Institute (IITRI), and the University of Illinois Chicago.
Purpose and Scope:
The PTTP contracts are integral to the NIH Blueprint Neurotherapeutics Network (BPN), a ‘virtual pharma’ initiative designed to provide the NIH research community with access to industry-standard therapeutic development services and expertise. These contracts support a broad range of preclinical pharmacology and toxicology testing activities essential for lead discovery, clinical candidate selection, and the generation of data required for regulatory submissions, such as Investigational New Drug (IND) applications to the FDA. The extension ensures continuity of these critical services while the PTTP requirement is recompeted and a new IDIQ contract is awarded.
Key Requirements and Objectives:
The primary objective of the PTTP is to assess the pharmacokinetics, toxicology, and safety of promising therapeutic candidates, facilitating their progression toward clinical use. The program anticipates receiving NIH-approved samples from diverse sources, including NIH-funded research programs, pharmaceutical and biotechnology companies, and other entities. Data generated through this program may be used by investigators to support IND applications.
Expected deliverables and services under the PTTP include, but are not limited to:
- Development and validation of analytical methods for quantifying drug or biologic concentrations in dosing solutions, biological fluids, and tissues.
- In vivo pharmacokinetic studies via various administration routes.
- Preclinical acute, subacute, subchronic, and long-term toxicity evaluations in both rodent and non-rodent species.
- Safety pharmacology studies (e.g., cardiovascular, pulmonary, central nervous system) in multiple species.
- Genotoxicity and carcinogenicity assessments using appropriate assay batteries.
- In vitro predictive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) assays, including metabolic stability, hepatotoxicity, permeability, cytochrome P450, plasma protein binding, and cytotoxicity studies.
Contracting Entity and Location:
The contracting entity is the National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA) office, located in Bethesda, Maryland, United States. The primary point of contact for this procurement is Sneha Singh, who can be reached at [email protected].
Classification and Regulatory Details:
- NAICS Code: 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), with a size standard of 1,000 employees.
- Product Service Code: AJ11.
- There is no set-aside for this procurement; it is not restricted to small businesses.
- The procurement is conducted under the authority of 41 U.S.C. 3304(a)(1) and FAR 6.103-1, which allows for non-competitive modifications when only one responsible source can satisfy agency requirements.
- The modification will incorporate all applicable provisions and clauses in accordance with Executive Order 14275 and OMB Memorandum M-25-26.
Special Considerations:
This notice is not a request for competitive proposals. However, interested parties may submit capability statements or objections to the proposed contract modification. The government will consider such responses for the purpose of determining whether to proceed on a non-competitive basis or to initiate a competitive procurement. All interested parties must have an active registration in the System for Award Management (SAM) and provide their Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification in any response.
Responses must be submitted electronically to Sneha Singh by August 18, 2026, at 3:00 pm Eastern Time, referencing notice 75N98026R00138.
Summary:
This contract extension ensures the uninterrupted provision of essential preclinical pharmacology and toxicology services that underpin the NIH’s drug development pipeline, particularly for neurological therapeutics. Contractors with expertise in pharmacokinetics, toxicology, safety pharmacology, and related analytical and regulatory support services may find this opportunity aligns with their capabilities, especially those with experience supporting IND-enabling studies and working within the NIH research ecosystem. The extension period allows for continued support of ongoing and new projects while the government prepares for a recompete of the PTTP requirement.
For further details, interested parties are encouraged to review the full notice at https://sam.gov/opp/8fe50589beca4284af505b7f685504f1/view and direct any inquiries to the contracting officer listed above.